Cargando…
SAT-LB031 Empagliflozin as an Add-On Medication to Subjects Uncontrolled on DPP4 Inhibitors and Metformin: Real World Data Supporting the Use of Empagliflozin as a Rational Second Add-On in Indian Type 2 Diabetic Patients
A huge burden of uncontrolled type 2 diabetes mellitus (T2D) prevails in the Indian settings with an estimated prevalence of patients with >7 % HbA1c at 63 %(1) and glycaemic control tends to decline over time with monotherapy(2). Newer guidelines supported the use of DPP4 inhibitors along with S...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552308/ http://dx.doi.org/10.1210/js.2019-SAT-LB031 |